Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000905148-25-001074
Filing Date
2025-04-03
Accepted
2025-04-03 16:28:42
Documents
2
Period of Report
2025-04-01

Document Format Files

Seq Description Document Type Size
1 form3.html 3  
1 form3.xml 3 6721
2 levy_poa.htm EX-24 11648
  Complete submission text file 0000905148-25-001074.txt   19719
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Issuer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 480 ARSENAL WAY SUITE 100 WATERTOWN MA 02472
Business Address
Levy Adam D. (Reporting) CIK: 0002061876 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-41551 | Film No.: 25809945